KALV
KalVista Pharmaceuticals, Inc.$26.75-0.01 (-0.06%)Prev Close$26.76·MCap$1.37B·P/E—·Vol7.66M·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
48
$7.40M
◆
Net Activity
Net Seller
$7.40M
●
Active Insiders
6
last 12 mo
Over the past 12 months, insider activity at KalVista Pharmaceuticals, Inc. (KALV) has been exclusively selling, with 0 insider purchases totaling $0.00 and 48 insider sales totaling $7.40M. The most recent insider transaction was by Palleiko Benjamin L (director, officer: CHIEF EXECUTIVE OFFICER), who sold $88.7K worth of shares on May 13, 2026. KalVista Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $1.37B.
KALV Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 13, 2026 | Palleiko Benjamin L | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 3,322 | $26.71 | $88.7K | 466,375 |
| Apr 20, 2026 | Palleiko Benjamin L | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 9,550 | $20.22 | $193.1K | 462,577 |
| Apr 20, 2026 | Piekos Brian | officer: Chief Financial Officer | Sell | 1,862 | $20.22 | $37.6K | 18,150 |
| Apr 20, 2026 | Sweeny Nicole | officer: Chief Commercial Officer | Sell | 1,862 | $20.22 | $37.6K | 51,391 |
| Apr 20, 2026 | Audhya Paul K. | officer: CHIEF MEDICAL OFFICER | Sell | 2,686 | $20.22 | $54.3K | 142,547 |
| Mar 27, 2026 | Venrock Healthcare Capital Partners III, L.P. | 10 percent owner | Sell | 214,631 | $17.20 | $3.69M | 5,129,500 |
| Mar 10, 2026 | Palleiko Benjamin L | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 6,693 | $16.08 | $107.6K | 451,815 |
| Feb 24, 2026 | Audhya Paul K. | officer: CHIEF MEDICAL OFFICER | Sell | 5,354 | $15.57 | $83.3K | 138,983 |
| Feb 24, 2026 | Palleiko Benjamin L | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 10,034 | $15.57 | $156.2K | 442,883 |
| Feb 24, 2026 | Piekos Brian | officer: Chief Financial Officer | Sell | 1,767 | $15.57 | $27.5K | 13,762 |
| Feb 24, 2026 | Sweeny Nicole | officer: Chief Commercial Officer | Sell | 3,975 | $15.57 | $61.9K | 47,003 |
| Feb 24, 2026 | Yea Christopher | officer: CHIEF DEVELOPMENT OFFICER | Sell | 4,347 | $15.57 | $67.7K | 226,701 |
| Feb 17, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 1,163 | $15.00 | $17.4K | 0 |
| Feb 17, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 1,038 | $15.00 | $15.6K | 0 |
| Feb 17, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 1,109 | $15.00 | $16.6K | 0 |
| Feb 13, 2026 | Palleiko Benjamin L | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 3,354 | $15.70 | $52.7K | 428,286 |
| Dec 9, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 7,294 | $16.51 | $120.4K | 424,520 |
| Dec 4, 2025 | Sweeny Nicole | Chief Commercial Officer | Sell | 3,813 | $13.45 | $51.3K | 39,728 |
| Nov 26, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 5,296 | $13.45 | $71.2K | 131,831 |
| Nov 26, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 10,940 | $13.45 | $147.2K | 416,189 |
| Nov 26, 2025 | Piekos Brian | Chief Financial Officer | Sell | 4,471 | $13.45 | $60.1K | 10,529-30% |
| Nov 26, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 4,331 | $13.45 | $58.3K | 223,508 |
| Nov 19, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 3,075 | $14.48 | $44.5K | 125,877 |
| Nov 19, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 4,466 | $14.48 | $64.7K | 403,879 |
| Nov 19, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 2,683 | $14.48 | $38.8K | 133,574 |
| Nov 13, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 3,328 | $11.55 | $38.4K | 398,981 |
| Sep 9, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 7,294 | $15.84 | $115.5K | 395,189 |
| Aug 26, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,336 | $13.42 | $31.3K | 122,505 |
| Aug 26, 2025 | Sweeny Nicole | Chief Commercial Officer | Sell | 1,480 | $13.42 | $19.9K | 32,291 |
| Aug 26, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 1,954 | $13.42 | $26.2K | 132,052 |
| Aug 25, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,942 | $13.22 | $38.9K | 119,841 |
| Aug 25, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 10,940 | $13.22 | $144.7K | 386,858 |
| Aug 25, 2025 | Sweeny Nicole | Chief Commercial Officer | Sell | 1,864 | $13.22 | $24.6K | 28,771 |
| Aug 25, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 2,362 | $13.22 | $31.2K | 130,881 |
| Aug 19, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,939 | $13.19 | $38.8K | 116,533 |
| Aug 19, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 4,409 | $13.19 | $58.1K | 374,548 |
| Aug 19, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 2,649 | $13.19 | $34.9K | 129,493 |
| Jul 10, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 32,979 | $15.69 | $517.5K | 369,595 |
| Jul 10, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 30,250 | $15.69 | $474.7K | 127,939 |
| Jun 10, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 7,169 | $14.50 | $104.0K | 315,074 |
| May 27, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,146 | $11.31 | $24.3K | 113,026 |
| May 27, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 1,926 | $11.31 | $21.8K | 98,189 |
| May 23, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,689 | $11.88 | $31.9K | 110,172 |
| May 23, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 9,999 | $11.88 | $118.7K | 306,618 |
| May 23, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 2,317 | $11.88 | $27.5K | 96,990 |
| May 20, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,776 | $11.84 | $32.9K | 106,611 |
| May 20, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 3,808 | $11.84 | $45.1K | 293,367 |
| May 20, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 2,600 | $11.84 | $30.8K | 95,557 |
| Apr 11, 2025 | Venrock Healthcare Capital Partners III, L.P. | Buy | 25,000 | $9.42 | $235.5K | 5,303,985 | |
| Mar 10, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 6,669 | $11.97 | $79.8K | 287,811 |
Showing 1–50 of 145
1 / 3
KALV Insider Buying Activity
The following table shows recent insider purchases of KalVista Pharmaceuticals, Inc. (KALV) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 11, 2025 | Venrock Healthcare Capital Partners III, L.P. | Buy | 25,000 | $9.42 | $235.5K | 5,303,985 |
KALV Insider Selling Activity
The following table shows recent insider sales of KalVista Pharmaceuticals, Inc. (KALV) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 13, 2026 | Palleiko Benjamin L | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 3,322 | $26.71 | $88.7K | 466,375 |
| Apr 20, 2026 | Palleiko Benjamin L | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 9,550 | $20.22 | $193.1K | 462,577 |
| Apr 20, 2026 | Piekos Brian | officer: Chief Financial Officer | Sell | 1,862 | $20.22 | $37.6K | 18,150 |
| Apr 20, 2026 | Sweeny Nicole | officer: Chief Commercial Officer | Sell | 1,862 | $20.22 | $37.6K | 51,391 |
| Apr 20, 2026 | Audhya Paul K. | officer: CHIEF MEDICAL OFFICER | Sell | 2,686 | $20.22 | $54.3K | 142,547 |
| Mar 27, 2026 | Venrock Healthcare Capital Partners III, L.P. | 10 percent owner | Sell | 214,631 | $17.20 | $3.69M | 5,129,500 |
| Mar 10, 2026 | Palleiko Benjamin L | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 6,693 | $16.08 | $107.6K | 451,815 |
| Feb 24, 2026 | Audhya Paul K. | officer: CHIEF MEDICAL OFFICER | Sell | 5,354 | $15.57 | $83.3K | 138,983 |
| Feb 24, 2026 | Palleiko Benjamin L | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 10,034 | $15.57 | $156.2K | 442,883 |
| Feb 24, 2026 | Piekos Brian | officer: Chief Financial Officer | Sell | 1,767 | $15.57 | $27.5K | 13,762 |
| Feb 24, 2026 | Sweeny Nicole | officer: Chief Commercial Officer | Sell | 3,975 | $15.57 | $61.9K | 47,003 |
| Feb 24, 2026 | Yea Christopher | officer: CHIEF DEVELOPMENT OFFICER | Sell | 4,347 | $15.57 | $67.7K | 226,701 |
| Feb 17, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 1,163 | $15.00 | $17.4K | 0 |
| Feb 17, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 1,038 | $15.00 | $15.6K | 0 |
| Feb 17, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 1,109 | $15.00 | $16.6K | 0 |
| Feb 13, 2026 | Palleiko Benjamin L | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 3,354 | $15.70 | $52.7K | 428,286 |
| Dec 9, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 7,294 | $16.51 | $120.4K | 424,520 |
| Dec 4, 2025 | Sweeny Nicole | Chief Commercial Officer | Sell | 3,813 | $13.45 | $51.3K | 39,728 |
| Nov 26, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 5,296 | $13.45 | $71.2K | 131,831 |
| Nov 26, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 10,940 | $13.45 | $147.2K | 416,189 |
| Nov 26, 2025 | Piekos Brian | Chief Financial Officer | Sell | 4,471 | $13.45 | $60.1K | 10,529-30% |
| Nov 26, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 4,331 | $13.45 | $58.3K | 223,508 |
| Nov 19, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 3,075 | $14.48 | $44.5K | 125,877 |
| Nov 19, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 4,466 | $14.48 | $64.7K | 403,879 |
| Nov 19, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 2,683 | $14.48 | $38.8K | 133,574 |
| Nov 13, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 3,328 | $11.55 | $38.4K | 398,981 |
| Sep 9, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 7,294 | $15.84 | $115.5K | 395,189 |
| Aug 26, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,336 | $13.42 | $31.3K | 122,505 |
| Aug 26, 2025 | Sweeny Nicole | Chief Commercial Officer | Sell | 1,480 | $13.42 | $19.9K | 32,291 |
| Aug 26, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 1,954 | $13.42 | $26.2K | 132,052 |
| Aug 25, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,942 | $13.22 | $38.9K | 119,841 |
| Aug 25, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 10,940 | $13.22 | $144.7K | 386,858 |
| Aug 25, 2025 | Sweeny Nicole | Chief Commercial Officer | Sell | 1,864 | $13.22 | $24.6K | 28,771 |
| Aug 25, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 2,362 | $13.22 | $31.2K | 130,881 |
| Aug 19, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,939 | $13.19 | $38.8K | 116,533 |
| Aug 19, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 4,409 | $13.19 | $58.1K | 374,548 |
| Aug 19, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 2,649 | $13.19 | $34.9K | 129,493 |
| Jul 10, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 32,979 | $15.69 | $517.5K | 369,595 |
| Jul 10, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 30,250 | $15.69 | $474.7K | 127,939 |
| Jun 10, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 7,169 | $14.50 | $104.0K | 315,074 |
| May 27, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,146 | $11.31 | $24.3K | 113,026 |
| May 27, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 1,926 | $11.31 | $21.8K | 98,189 |
| May 23, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,689 | $11.88 | $31.9K | 110,172 |
| May 23, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 9,999 | $11.88 | $118.7K | 306,618 |
| May 23, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 2,317 | $11.88 | $27.5K | 96,990 |
| May 20, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,776 | $11.84 | $32.9K | 106,611 |
| May 20, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 3,808 | $11.84 | $45.1K | 293,367 |
| May 20, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 2,600 | $11.84 | $30.8K | 95,557 |
| Mar 10, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 6,669 | $11.97 | $79.8K | 287,811 |
KALV Insiders
Venrock Healthcare Capital Partners III, L.P.
10% Owner
Bought $19.44MSold $3.69M
14 tradesLast: Mar 27, 2026
Similar Stocks to KALV
VRTX
Vertex Pharmaceuticals Incorporated
$436.80-3.02%
$114.32B
REGN
Regeneron Pharmaceuticals, Inc.
$699.83-1.87%
$73.44B
ALNY
Alnylam Pharmaceuticals, Inc.
$289.07-1.46%
$39.18B
RVMD
Revolution Medicines, Inc.
$145.16-2.80%
$31.78B
INSM
Insmed Incorporated
$109.78-5.14%
$25.06B
UTHR
United Therapeutics Corporation
$568.58-1.47%
$24.13B
ROIV
Roivant Sciences Ltd.
$29.29-0.08%
$20.96B
MRNA
Moderna, Inc.
$49.04-2.34%
$19.46B